ArticleJAMA network open2021

Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity.

Jiaqiang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.